Lv1
10 积分 2026-06-15 加入
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial
9小时前
已完结
小细胞肺癌免疫治疗专家共识(2025版)
1个月前
已完结
Autoimmune Hemolytic Anemias
2个月前
已完结
Evolution and trajectory of B-cell targeted therapies in rheumatic diseases
2个月前
已完结